News
Hosted on MSN5mon
FDA grants fast track status to FELIQS’s FLQ-101 to prevent ROPThe US Food and Drug Administration (FDA) has granted fast track designation to FELIQS’ lead product FLQ-101, for preventing retinopathy of prematurity (ROP). FLQ-101, which can be administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback